We are pleased to share our Annual Report covering activity & financial reports in the period 1st October 2023 to 30th September 2024. Please click here to access the full report. You can find out more about our goals, research activity, the Arcs, fundraising, parent/patient involvement and engagement in research and the future.
Headlines
- Over £980K generated during this period
- Over £600K invested in rhabdomyosarcoma research during the period
- 7 new Arcs joined our existing 24 Arcs in the UK
- Proud to be funding 13 RMS research projects across research institutions in the UK
- Our community of parents, patients and other family members continues to grow and contributes to advocacy work
- Hosted two family research engagement days at Wellcome Sanger and the University of Birmingham
- Fundraising continues to be driven by a passionate patient community, with ever-increasing corporate donations & partnerships.
We remain eternally grateful to the families, scientists, clinicians and other medical professionals. This is an ongoing and heart breaking fight against rhabdomyosarcoma. Thanks for always motivating us to persevere. Together we are stronger. This work is for all those who have, and will, have the misfortune of hearing the word ‘rhabdomyosarcoma’.
